INBS
INTELLIGENT BIO SOLUTIONS INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.53
+2.00%Year over year
Reported trailing growth
- Revenue
- +38.1%
- EBITDA
- -23.7%
- EBIT
- -18.8%
- EPS
- +54.5%
- Free cash flow
- -23.2%
- Operating cash flow
- -24.8%
Forward estimates
Based on analyst estimates
- Revenue
- +58.9%
- EBITDA
- -15.9%
- EPS
- +47.1%
Three-year CAGR
- Revenue
- +49.7%
- EBITDA
- -22.6%
- EBIT
- -18.4%
- Net income
- -17.6%
- EPS
- +57.8%
- Free cash flow
- -21.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026